Atossa Therapeutics (NASDAQ:ATOS) Releases Quarterly Earnings Results

Atossa Therapeutics (NASDAQ:ATOS) released its earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, Yahoo Finance reports.

Atossa Therapeutics Stock Down 8.0 %

Shares of NASDAQ:ATOS opened at $1.84 on Wednesday. Atossa Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $2.11. The firm has a 50-day simple moving average of $1.17 and a 200 day simple moving average of $0.90.

Institutional Investors Weigh In On Atossa Therapeutics

A number of institutional investors have recently modified their holdings of ATOS. Millennium Management LLC bought a new stake in shares of Atossa Therapeutics during the 2nd quarter valued at about $1,673,000. Renaissance Technologies LLC boosted its stake in Atossa Therapeutics by 79.5% during the 1st quarter. Renaissance Technologies LLC now owns 2,100,492 shares of the company’s stock valued at $2,626,000 after purchasing an additional 930,152 shares during the period. Bank of Montreal Can acquired a new position in Atossa Therapeutics during the 2nd quarter valued at about $365,000. GSA Capital Partners LLP boosted its stake in Atossa Therapeutics by 29.3% during the 4th quarter. GSA Capital Partners LLP now owns 449,082 shares of the company’s stock valued at $395,000 after purchasing an additional 101,690 shares during the period. Finally, State Street Corp boosted its stake in Atossa Therapeutics by 4.2% during the 1st quarter. State Street Corp now owns 2,233,010 shares of the company’s stock valued at $2,791,000 after purchasing an additional 90,960 shares during the period. Institutional investors own 12.74% of the company’s stock.

Analyst Ratings Changes

ATOS has been the subject of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Atossa Therapeutics in a research report on Friday, January 12th. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Atossa Therapeutics in a research report on Tuesday. Finally, StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 18th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.